CG Pharmaceuticals, operating under the umbrella of CrystalGenomics, positions itself as a leader in the field of drug discovery through the innovative use of structural chemoproteomics. Founded in 2000, this bi-national entity boasts a presence both in Seoul, Korea, and Emeryville, California, making it well-poised for global clinical management.
The company operates within key industries including Biotechnology, Health Care, and Pharmaceutical. This strategic positioning aligns with its forward-thinking slogan of being "a pioneering chemoproteiomics-based drug discovery and development firm."
In its latest funding round, the company secured a $12.80M Series B investment on 25 June 2014 from the Global Pharmaceutical Industry Development Fund. This capital injection is indicative of strong investor confidence and supports the company's international expansion goals.
